Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis.

Korkmaz, T; Seber, S; Kefeli, UMUT; Sari, E; Canhoroz, M; Oven, B; Yildirim, E; Yasar, N; Aydin, D; Balvan, O; Sener, N; Yuksel, S; Mert, A; Polat, O; Yumuk, F; Kanat, O; Gumus, M; Turhal, NS

doi:10.1007/s12094-012-0960-6

Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis.

Korkmaz T., Seber S., Kefeli U., Sari E., Canhoroz M., Oven B., ...Daha Fazla

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, cilt.15, ss.535-40, 2013 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 15
Basım Tarihi: 2013
Doi Numarası: 10.1007/s12094-012-0960-6
Dergi Adı: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.535-40
Anahtar Kelimeler: Platinum sensitive disease, Platinum refracter disease, Second-line chemotherapy, Small cell lung cancer, PHASE-II, TOPOTECAN, CHEMOTHERAPY, ETOPOSIDE, CISPLATIN, PROGRESS, THERAPY, TRIAL, CARE
Kocaeli Üniversitesi Adresli: Evet